(BCPC) Balchem - Overview
Exchange: NASDAQ •
Country: United States •
Currency: USD •
Type: Common Stock •
ISIN: US0576652004
Stock: Nutrients, Chemicals, Ingredients, Sterilization, Fumigants
Total Rating 54
Risk 76
Buy Signal -0.50
| Risk 5d forecast | |
|---|---|
| Volatility | 23.0% |
| Relative Tail Risk | -8.01% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.00 |
| Alpha | -11.33 |
| Character TTM | |
|---|---|
| Beta | 0.447 |
| Beta Downside | 0.880 |
| Drawdowns 3y | |
|---|---|
| Max DD | 23.10% |
| CAGR/Max DD | 0.49 |
EPS (Earnings per Share)
Revenue
Description: BCPC Balchem March 05, 2026
Balchem Corporation (BCPC) develops and distributes specialty ingredients across nutritional, food, pharmaceutical, and industrial markets. The company operates in three segments: Human Nutrition and Health, Animal Nutrition and Health, and Specialty Products. This business model focuses on high-value, specialized chemical applications rather than bulk commodity chemicals.
The Human Nutrition and Health segment provides ingredients for food and beverages, including spray-dried powders, lipid systems, and specialty vitamin K2. This segment caters to the growing demand for fortified and functional food products.
The Animal Nutrition and Health segment supplies microencapsulated products and chelation technology for animal health and milk production. This segment addresses the need for efficient nutrient delivery in livestock and companion animals.
The Specialty Products segment distributes ethylene oxide for medical device sterilization and propylene oxide as a fumigant. This segment serves niche markets requiring highly specialized chemical solutions.
Balchem sells its products through direct sales, independent distributors, and sales agents. Investors may find further detailed analysis on ValueRay helpful for a deeper understanding of BCPCs market position and financial performance.
Headlines to watch out for
- Demand for human and animal nutrition products drives revenue growth
- Ethylene oxide sales to healthcare industry impact specialty products
- Raw material costs for specialty ingredients affect profitability
- Regulatory changes in food and animal health sectors pose risks
Piotroski VR‑10 (Strict, 0-10) 8.5
| Net Income: 154.8m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.13 > 0.02 and ΔFCF/TA 3.39 > 1.0 |
| NWC/Revenue: 18.24% < 20% (prev 16.37%; Δ 1.88% < -1%) |
| CFO/TA 0.13 > 3% & CFO 216.6m > Net Income 154.8m |
| Net Debt (117.4m) to EBITDA (265.3m): 0.44 < 3 |
| Current Ratio: 2.07 > 1.5 & < 3 |
| Outstanding Shares: last quarter (32.3m) vs 12m ago -0.70% < -2% |
| Gross Margin: 35.74% > 18% (prev 0.35%; Δ 3.54k% > 0.5%) |
| Asset Turnover: 63.19% > 50% (prev 60.54%; Δ 2.65% > 0%) |
| Interest Coverage Ratio: 20.48 > 6 (EBITDA TTM 265.3m / Interest Expense TTM 10.2m) |
Altman Z'' 6.44
| A: 0.11 (Total Current Assets 365.6m - Total Current Liabilities 176.4m) / Total Assets 1.71b |
| B: 0.66 (Retained Earnings 1.12b / Total Assets 1.71b) |
| C: 0.13 (EBIT TTM 209.2m / Avg Total Assets 1.64b) |
| D: 2.59 (Book Value of Equity 1.17b / Total Liabilities 450.1m) |
| Altman-Z'' Score: 6.44 = AAA |
Beneish M -2.94
| DSRI: 1.10 (Receivables 143.6m/119.7m, Revenue 1.04b/953.7m) |
| GMI: 0.99 (GM 35.74% / 35.25%) |
| AQI: 0.98 (AQ_t 0.60 / AQ_t-1 0.61) |
| SGI: 1.09 (Revenue 1.04b / 953.7m) |
| TATA: -0.04 (NI 154.8m - CFO 216.6m) / TA 1.71b) |
| Beneish M-Score: -2.94 (Cap -4..+1) = A |
What is the price of BCPC shares?
As of March 15, 2026, the stock is trading at USD 170.91 with a total of 124,994 shares traded.
Over the past week, the price has changed by -3.57%, over one month by -6.52%, over three months by +7.16% and over the past year by +2.14%.
Over the past week, the price has changed by -3.57%, over one month by -6.52%, over three months by +7.16% and over the past year by +2.14%.
Is BCPC a buy, sell or hold?
Balchem has received a consensus analysts rating of 4.00.
Therefore, it is recommended to buy BCPC.
- StrongBuy: 0
- Buy: 2
- Hold: 0
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the BCPC price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 200.5 | 17.3% |
| Analysts Target Price | 200.5 | 17.3% |
BCPC Fundamental Data Overview March 14, 2026
P/E Trailing = 36.9011
P/E Forward = 33.1126
P/S = 5.4733
P/B = 4.4678
P/EG = 4.7283
Revenue TTM = 1.04b USD
EBIT TTM = 209.2m USD
EBITDA TTM = 265.3m USD
Long Term Debt = 164.0m USD (from longTermDebt, last quarter)
Short Term Debt = 3.82m USD (from shortTermDebt, last quarter)
Debt = 192.0m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 117.4m USD (from netDebt column, last quarter)
Enterprise Value = 5.79b USD (5.68b + Debt 192.0m - CCE 74.6m)
Interest Coverage Ratio = 20.48 (Ebit TTM 209.2m / Interest Expense TTM 10.2m)
EV/FCF = 26.76x (Enterprise Value 5.79b / FCF TTM 216.6m)
FCF Yield = 3.74% (FCF TTM 216.6m / Enterprise Value 5.79b)
FCF Margin = 20.88% (FCF TTM 216.6m / Revenue TTM 1.04b)
Net Margin = 14.93% (Net Income TTM 154.8m / Revenue TTM 1.04b)
Gross Margin = 35.74% ((Revenue TTM 1.04b - Cost of Revenue TTM 666.5m) / Revenue TTM)
Gross Margin QoQ = 35.62% (prev 35.68%)
Tobins Q-Ratio = 3.39 (Enterprise Value 5.79b / Total Assets 1.71b)
Interest Expense / Debt = 1.13% (Interest Expense 2.18m / Debt 192.0m)
Taxrate = 21.60% (10.8m / 50.0m)
NOPAT = 164.0m (EBIT 209.2m * (1 - 21.60%))
Current Ratio = 2.07 (Total Current Assets 365.6m / Total Current Liabilities 176.4m)
Debt / Equity = 0.15 (Debt 192.0m / totalStockholderEquity, last quarter 1.26b)
Debt / EBITDA = 0.44 (Net Debt 117.4m / EBITDA 265.3m)
Debt / FCF = 0.54 (Net Debt 117.4m / FCF TTM 216.6m)
Total Stockholder Equity = 1.26b (last 4 quarters mean from totalStockholderEquity)
RoA = 9.43% (Net Income 154.8m / Total Assets 1.71b)
RoE = 12.31% (Net Income TTM 154.8m / Total Stockholder Equity 1.26b)
RoCE = 14.72% (EBIT 209.2m / Capital Employed (Equity 1.26b + L.T.Debt 164.0m))
RoIC = 11.45% (NOPAT 164.0m / Invested Capital 1.43b)
WACC = 7.34% (E(5.68b)/V(5.87b) * Re(7.56%) + D(192.0m)/V(5.87b) * Rd(1.13%) * (1-Tc(0.22)))
Discount Rate = 7.56% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.95%
Shares Correlation 3-Years: -33.33 | Cagr: -0.24%
[DCF] Terminal Value 83.43% ; FCFF base≈188.5m ; Y1≈232.5m ; Y5≈395.9m
[DCF] Fair Price = 237.2 (EV 7.71b - Net Debt 117.4m = Equity 7.60b / Shares 32.0m; r=7.34% [WACC]; 5y FCF grow 25.0% → 2.90% )
EPS Correlation: 81.42 | EPS CAGR: 6.62% | SUE: 2.55 | # QB: 3
Revenue Correlation: 75.74 | Revenue CAGR: 3.84% | SUE: 0.77 | # QB: 0
EPS next Quarter (2026-06-30): EPS=1.41 | Chg7d=+0.035 | Chg30d=+0.035 | Revisions Net=+2 | Analysts=2
EPS current Year (2026-12-31): EPS=5.69 | Chg7d=+0.113 | Chg30d=+0.113 | Revisions Net=+3 | Growth EPS=+10.4% | Growth Revenue=+6.3%
EPS next Year (2027-12-31): EPS=6.07 | Chg7d=+0.132 | Chg30d=+0.132 | Revisions Net=+3 | Growth EPS=+6.8% | Growth Revenue=+4.9%
[Analyst] Revisions Ratio: +1.00 (2 Up / 0 Down within 30d for Next Quarter)
[Growth] Implied Growth Rate = 5.2% (Discount Rate 7.9% - Earnings Yield 2.7%)
[Growth] Growth Spread = -0.0% (Analyst 5.2% - Implied 5.2%)
P/E Forward = 33.1126
P/S = 5.4733
P/B = 4.4678
P/EG = 4.7283
Revenue TTM = 1.04b USD
EBIT TTM = 209.2m USD
EBITDA TTM = 265.3m USD
Long Term Debt = 164.0m USD (from longTermDebt, last quarter)
Short Term Debt = 3.82m USD (from shortTermDebt, last quarter)
Debt = 192.0m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 117.4m USD (from netDebt column, last quarter)
Enterprise Value = 5.79b USD (5.68b + Debt 192.0m - CCE 74.6m)
Interest Coverage Ratio = 20.48 (Ebit TTM 209.2m / Interest Expense TTM 10.2m)
EV/FCF = 26.76x (Enterprise Value 5.79b / FCF TTM 216.6m)
FCF Yield = 3.74% (FCF TTM 216.6m / Enterprise Value 5.79b)
FCF Margin = 20.88% (FCF TTM 216.6m / Revenue TTM 1.04b)
Net Margin = 14.93% (Net Income TTM 154.8m / Revenue TTM 1.04b)
Gross Margin = 35.74% ((Revenue TTM 1.04b - Cost of Revenue TTM 666.5m) / Revenue TTM)
Gross Margin QoQ = 35.62% (prev 35.68%)
Tobins Q-Ratio = 3.39 (Enterprise Value 5.79b / Total Assets 1.71b)
Interest Expense / Debt = 1.13% (Interest Expense 2.18m / Debt 192.0m)
Taxrate = 21.60% (10.8m / 50.0m)
NOPAT = 164.0m (EBIT 209.2m * (1 - 21.60%))
Current Ratio = 2.07 (Total Current Assets 365.6m / Total Current Liabilities 176.4m)
Debt / Equity = 0.15 (Debt 192.0m / totalStockholderEquity, last quarter 1.26b)
Debt / EBITDA = 0.44 (Net Debt 117.4m / EBITDA 265.3m)
Debt / FCF = 0.54 (Net Debt 117.4m / FCF TTM 216.6m)
Total Stockholder Equity = 1.26b (last 4 quarters mean from totalStockholderEquity)
RoA = 9.43% (Net Income 154.8m / Total Assets 1.71b)
RoE = 12.31% (Net Income TTM 154.8m / Total Stockholder Equity 1.26b)
RoCE = 14.72% (EBIT 209.2m / Capital Employed (Equity 1.26b + L.T.Debt 164.0m))
RoIC = 11.45% (NOPAT 164.0m / Invested Capital 1.43b)
WACC = 7.34% (E(5.68b)/V(5.87b) * Re(7.56%) + D(192.0m)/V(5.87b) * Rd(1.13%) * (1-Tc(0.22)))
Discount Rate = 7.56% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.95%
Shares Correlation 3-Years: -33.33 | Cagr: -0.24%
[DCF] Terminal Value 83.43% ; FCFF base≈188.5m ; Y1≈232.5m ; Y5≈395.9m
[DCF] Fair Price = 237.2 (EV 7.71b - Net Debt 117.4m = Equity 7.60b / Shares 32.0m; r=7.34% [WACC]; 5y FCF grow 25.0% → 2.90% )
EPS Correlation: 81.42 | EPS CAGR: 6.62% | SUE: 2.55 | # QB: 3
Revenue Correlation: 75.74 | Revenue CAGR: 3.84% | SUE: 0.77 | # QB: 0
EPS next Quarter (2026-06-30): EPS=1.41 | Chg7d=+0.035 | Chg30d=+0.035 | Revisions Net=+2 | Analysts=2
EPS current Year (2026-12-31): EPS=5.69 | Chg7d=+0.113 | Chg30d=+0.113 | Revisions Net=+3 | Growth EPS=+10.4% | Growth Revenue=+6.3%
EPS next Year (2027-12-31): EPS=6.07 | Chg7d=+0.132 | Chg30d=+0.132 | Revisions Net=+3 | Growth EPS=+6.8% | Growth Revenue=+4.9%
[Analyst] Revisions Ratio: +1.00 (2 Up / 0 Down within 30d for Next Quarter)
[Growth] Implied Growth Rate = 5.2% (Discount Rate 7.9% - Earnings Yield 2.7%)
[Growth] Growth Spread = -0.0% (Analyst 5.2% - Implied 5.2%)